Skip to content

US · ZBIO · BIOTECHNOLOGY

Zenas BioPharma, Inc. (ZBIO) intrinsic value and stock valuation

$23.85as of 2026-11-21 · Mkt cap 2.01B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zenas BioPharma, Inc. DCF and intrinsic value

InvestorsCraft values ZBIO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ZBIO’s statements →

Zenas BioPharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 zenasbio.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$10M
20222025
Net income
-$-377.74M
20222025
Free cash flow
-$-172.35M
20222025
Total equity
$242.1M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$10M$5M$50M$0.00
Operating income-$-211.38M-$-163.89M-$-37.15M-$-76.2M
Net income-$-377.74M-$-156.99M-$-37.12M-$-119.28M
EPSd-$-8.44M-$-3.76M-$-968.68K-$-3.11M
Operating cash flow-$-172.33M-$-119.67M-$-30.53M-$-65.65M
Capital expenditure-$-20K-$-130K-$-20K-$-2.2M
Free cash flow-$-172.35M-$-119.81M-$-30.55M-$-67.85M
Total assets$383.6M$370M$68.2M$74.6M
Total debt$80M$1M$21.1M$1.53M
Net debt-$-30.68M-$-318.74M-$-35.74M-$-65.68M
Total equity$242.1M$312.5M-$-225.72M-$-192.29M
Cash and short-term investments$343.2M$350.8M$56.9M$67.2M
Income statement
2025202420232022
Revenue$10M$5M$50M$0.00
Cost of revenue$0.00$139.1M$0.00$61.7M
Gross profit$10M-$-134.14M$50M-$-61.69M
Research and development expenses$168.1M$139.1M$60M$62.7M
Selling, general and administrative expenses$53.3M$29.8M$17.1M$13.5M
Other expenses$0.00-$-139.14M$10M-$-61.69M
Operating expenses$221.4M$29.8M$87.2M$14.5M
Cost and expenses$221.4M$168.9M$87.2M$76.2M
Interest income$12.2M$0.00$0.00$0.00
Interest expense$7.33M$0.00$0.00$0.00
Depreciation and amortization$60K$140K$110K$80K
Ebitda-$-370.43M-$-156.42M-$-27.03M-$-75.12M
Operating income-$-211.38M-$-163.89M-$-37.15M-$-76.2M
Total other income/expenses, net-$-166.43M$7.33M$320K-$-43.08M
Income before tax-$-377.82M-$-156.56M-$-36.82M-$-119.28M
Income tax expense-$-80K$430K$300K$0.00
Net income-$-377.74M-$-156.99M-$-37.12M-$-119.28M
Weighted average shares outstanding$44.7M$41.8M$38.3M$38.3M
Weighted average diluted shares outstanding$44.7M$41.8M$38.3M$38.3M
Balance sheet
2025202420232022
Cash and short-term investments$343.2M$350.8M$56.9M$67.2M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$351.2M$355.9M$59.8M$68.4M
Property, plant and equipment, net$1.39M$1.19M$1.01M$1.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$17.3M$0.00$0.00$0.00
Total non-current assets$32.5M$14M$8.38M$6.13M
Total assets$383.6M$370M$68.2M$74.6M
Accounts payable$7.11M$17.1M$5.4M$5.82M
Short-term debt$1.11M$790K$560K$710K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$62.7M$57.3M$23.3M$26M
Long-term debt$78.9M$220K$20.6M$810K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$78.9M$220K$270.6M$240.9M
Capital lease obligations$210K$1M$810K$1.53M
Total liabilities$141.5M$57.5M$293.9M$266.9M
Common stock$10K$0.00$0.00$0.00
Retained earnings-$-765.13M-$-387.39M-$-230.4M-$-193.28M
Accumulated other comprehensive income (loss)-$-60K$190K$40K-$-40K
Total equity$242.1M$312.5M-$-225.72M-$-192.29M
Total investments$249.8M$31M$0.00$0.00
Total debt$80M$1M$21.1M$1.53M
Net debt-$-30.68M-$-318.74M-$-35.74M-$-65.68M
Cash flow statement
2025202420232022
Net income-$-377.74M-$-156.99M-$-37.12M-$-119.28M
Depreciation and amortization-$-1.88M$140K$110K$80K
Stock-based compensation$26.4M$10.8M$3.5M$740K
Change in working capital$950K$25.4M-$-8.04M$7.97M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-10.04M$11.7M-$-420K$1.09M
Net cash provided by operating activities-$-172.33M-$-119.67M-$-30.53M-$-65.65M
Investments in property, plant and equipment-$-20K-$-130K-$-20K-$-200K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-251.89M-$-30.55M-$-20K-$-2.2M
Common stock issued$152.9M$240.6M$120K$59.4M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$215.3M$413M$20.1M$59.4M
Net change in cash-$-209.19M$262.9M-$-10.35M-$-8.5M
Cash at end of period$110.6M$319.8M$56.9M$67.3M
Operating cash flow-$-172.33M-$-119.67M-$-30.53M-$-65.65M
Capital expenditure-$-20K-$-130K-$-20K-$-2.2M
Free cash flow-$-172.35M-$-119.81M-$-30.55M-$-67.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zenas BioPharma, Inc.

        Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

        CEO
        Leon Oliver Moulder Jr.
        Employees
        167
        Beta
        -1.01

        Explore

        Frequently asked questions

        What is the intrinsic value of Zenas BioPharma, Inc. (ZBIO)?

        Zenas BioPharma, Inc. (ZBIO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZBIO undervalued?

        ZBIO trades at a price of $23.85 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.